BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $488,754 | +61.3% | 69,033 | +187.2% | 0.01% | +11.1% |
| Q3 2022 | $303,000 | +27.8% | 24,034 | +65.2% | 0.01% | +28.6% |
| Q1 2022 | $237,000 | +51.0% | 14,548 | +28.7% | 0.01% | +40.0% |
| Q4 2021 | $157,000 | -79.6% | 11,308 | -76.8% | 0.01% | -84.8% |
| Q2 2021 | $769,000 | +605.5% | 48,641 | +231.8% | 0.03% | +725.0% |
| Q4 2020 | $109,000 | +127.1% | 14,658 | +5.0% | 0.00% | +100.0% |
| Q3 2020 | $48,000 | -33.3% | 13,964 | -7.8% | 0.00% | 0.0% |
| Q2 2020 | $72,000 | +26.3% | 15,140 | -46.6% | 0.00% | 0.0% |
| Q1 2020 | $57,000 | -94.6% | 28,368 | -77.6% | 0.00% | -84.6% |
| Q1 2017 | $1,063,000 | +431.5% | 126,553 | +551.5% | 0.01% | +550.0% |
| Q4 2015 | $200,000 | – | 19,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |